St Jude forms new business unit:
This article was originally published in Clinica
St Jude Medical has created a tachycardia strategic business unit at its Pacemaker division. Dr Mark Kroll, who has been appointed vice-president to head the unit, moves from Angeion where he was vice-president of research and product planning. St Jude has a 6.5% holding in Angeion, with which it has an agreement for the global distribution of Sentinel, the smallest implantable cardiac defibrillator developed by Angeion which will be marketed under the Pacesetter brand. Angeion has just received an IDE from the US FDA to perform up to 60 implants of the Sentinel device in 15 centres.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.